Free Trial
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel
NASDAQ:PLUR

Pluri 11/12/2024 Earnings Results & Report

Pluri logo
$0.93 -0.01 (-1.06%)
Closing price 10/14/2026 03:54 PM Eastern
Extended Trading
$0.94 +0.01 (+1.18%)
As of 08:55 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pluri reported earnings on November 12, 2024. The company reported EPS of -$1.08, while revenue was $0.33 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Report Date
Time
After Market Closes

Pluri EPS Results

Actual EPS
-$1.08
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 4 quarters

Pluri Revenue Results

Actual Revenue
$0.33 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Pluri's next earnings date is estimated for Thursday, November 5, 2026, based on past reporting schedules.

Conference Call Resources

Pluri Earnings FAQ

Pluri (NASDAQ:PLUR) reported earnings of -$1.08 per share for the quarter. The report was announced on Tuesday, November 12, 2024.

Pluri reported revenue of $0.33 million for the quarter.

Pluri's next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Pluri on the company's earnings history page.

Pluri Earnings Headlines

Ever After Foods and Roslin Technologies Achieve Major Leap in Cultivated Meat Productivity
October 13 at 7:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/13/3379504/0/en/ever-after-foods-and-roslin-technologies-achieve-major-leap-in-cultivated-meat-productivity.html
Pluri (NASDAQ:PLUR) Shares Climb 5.1% - Here's Why
October 8, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31097918
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.tc pixel
October 15 at 1:00 AM  |  Investors Alley (Ad)
Pluri Inc. Reports Earnings Results for the Full Year Ended June 30, 2026
September 10, 2026  |  marketscreener.comM
Pluri Announces August 2026 Equity Financing Transaction
August 28, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/pluri-announces-august-2026-equity-financing-transaction?utm_source=marketbeat.com&utm_medium=referral
Pluri prices $3.3 million offering
August 27, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4637455-pluri-prices-33-million-offering
See More Pluri Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pluri? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pluri and other key companies, straight to your email.

About Pluri

Pluri (NASDAQ:PLUR) (NASDAQ: PLUR), formerly known as Pluristem Therapeutics, is a biotechnology company developing cell-based products using its proprietary three-dimensional cell expansion platform. The company’s technology is designed to produce large quantities of allogeneic cells, which are cells intended for use in patients other than the original donor, without requiring a tissue match.

Pluri’s research has focused primarily on placenta-derived stromal cells, marketed under the PLX platform. Its development programs have explored potential applications in regenerative medicine, including conditions involving tissue damage, inflammation, blood disorders and immune-related diseases. The company has also investigated cell-based solutions for areas beyond traditional therapeutics, including food technology and agricultural applications.

Founded as Pluristem Therapeutics, the company changed its name to Pluri as it broadened its focus beyond drug development. Pluri is based in Haifa, Israel, and its activities have included research collaborations and development efforts aimed at serving international healthcare and biotechnology markets. Yaky Yanay has served as the company’s chief executive officer.

View Pluri Profile
Earnings Tools